Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Evaluating Impact of Insertion Length on Clinical Outcomes in FLT3-ITD Mutated AML: A Single Center Retrospective Analysis

Blood (2024) 144 (Supplement 1): 6143.

https://doi.org/10.1182/blood-2024-209265

Published: 2024

Journal Articles

Impact of P190 and P210 BCR::ABL1 Chimeric Protein on Outcomes of Acute Lymphoblastic Leukemia at a Tertiary Center

Ahmed N Mohamed, Meera Patel, Hadil Zureigat, Daniel P. Nurse, Sara F Haddad, Emily C. Zabor, Yohana B. Bedelu, Mark Jinan Chen, Joy Nakitandwe, John C. Molina, Sophia Balderman, Akriti G. Jain, Abhay Singh, Sudipto Mukherjee, Aaron T. Gerds, Hetty E. Carraway, Anjali S. Advani, Moaath K. Mustafa Ali

Blood (2024) 144 (Supplement 1): 5909.

https://doi.org/10.1182/blood-2024-202558

Published: 2024

Journal Articles

Outcomes of Accelerated and Blast Phase Chronic Myeloid Leukemia at a Tertiary Center

Ahmed N Mohamed, Hadil Zureigat, Muaz Alsabbagh Alchirazi, Aastha Dhakal, Ali Mushtaq, Naveen Rehman, Bryan Berube, Sneha Govande, Emily C. Zabor, Akriti G. Jain, John C. Molina, Sophia Balderman, Abhay Singh, Aaron T. Gerds, Anjali S. Advani, Hetty E. Carraway, Matt Kalaycio, Sudipto Mukherjee, Moaath K. Mustafa Ali

Blood (2024) 144 (Supplement 1): 6610.

https://doi.org/10.1182/blood-2024-210152

Published: 2024

Journal Articles

Genetic Profiling and Survival Analysis of Patients with Acute Myeloid Leukemia and a History of Autoimmune Disease

Blood (2024) 144 (Supplement 1): 6127.

https://doi.org/10.1182/blood-2024-199358

Published: 2024

Journal Articles

A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes

Somedeb Ball, Najla H. Al Ali, Akriti G. Jain, Moazzam Shahzad, Junmin Whiting, Daniel Lastorino, Zhuoer Xie, Alison R. Walker, Onyee Chan, Eric Padron, Jongphil Kim, Jeffrey E Lancet, David Sallman, Sara M. Tinsley-Vance, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 532.

https://doi.org/10.1182/blood-2024-209273

Published: 2024

Journal Articles

Outcomes of Blast-Phase MPN and JAK2 , MPL , and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2 , MPL , and CALR Genes: A Propensity Score-Adjusted Cohort Study

Blood (2024) 144 (Supplement 1): 2868.

https://doi.org/10.1182/blood-2024-207748

Published: 2024

Journal Articles

Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia

Justin Grenet, Neela Easwar, Akriti G. Jain, Madelyn Burkart, Xiaoyue Ma, Paul Christos, Ellen K. Ritchie, Michael Samuel, Justin D. Kaner, Jonathan Canaani, Aaron D. Goldberg, Shira N. Dinner, Kendra L. Sweet, Gail J. Roboz, Pinkal Desai

Blood (2024) 144 (Supplement 1): 2867.

https://doi.org/10.1182/blood-2024-206340

Published: 2024

Journal Articles

Impact of Cytogenetic Response on Long-Term Survival in Acute Myeloid Leukemia: A Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 2862.

https://doi.org/10.1182/blood-2024-202134

Published: 2024

Journal Articles

Salvage Reinduction Chemotherapy Versus Alternative Regimens after Failed AML Intensive Induction Regimen, a Single Center Experience

Blood (2024) 144 (Supplement 1): 2848.

https://doi.org/10.1182/blood-2024-202525

Published: 2024

Journal Articles

Impact of Non- ABL1 Mutations on Outcomes in Patients with Chronic Myeloid Leukemia

Akriti G. Jain, Joy Nakitandwe, Krishna Desai, Genevieve M Crane, David S. Bosler, Jill O'Brien, Moaath K. Mustafa Ali, John C. Molina, Sophia Balderman, Anjali S. Advani, Hetty E. Carraway, Aaron T. Gerds, Abhay Singh, Matt Kalaycio, Sudipto Mukherjee

Blood (2024) 144 (Supplement 1): 3153.

https://doi.org/10.1182/blood-2024-209165

Published: 2024

Journal Articles

Cardiovascular Profile of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia: A 16-Year Observational Study

Blood (2024) 144 (Supplement 1): 1777.

https://doi.org/10.1182/blood-2024-212146

Published: 2024

Journal Articles

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update

Blood (2024) 144 (Supplement 1): 219.

https://doi.org/10.1182/blood-2024-200393

Published: 2024

Journal Articles

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Blood (2024) 144 (Supplement 1): 2426.

https://doi.org/10.1182/blood-2024-207278

Published: 2024

Journal Articles

Outcomes of Second-Line Tyrosine Kinase Inhibitors after First-Line Imatinib in Chronic Myelogenous Leukemia: A Retrospective Cohort Study

Muaz Alsabbagh Alchirazi, Hadil Zureigat, Ahmed N Mohamed, Aastha Dhakal, Ali Mushtaq, Naveen Rehman, Bryan Berube, Sneha Govande, Emily C. Zabor, Akriti G. Jain, John C. Molina, Sophia Balderman, Abhay Singh, Aaron T. Gerds, Anjali S. Advani, Hetty E. Carraway, Matt Kalaycio, Sudipto Mukherjee, Moaath K. Mustafa Ali

Blood (2024) 144 (Supplement 1): 6597.

https://doi.org/10.1182/blood-2024-206448

Published: 2024

Journal Articles

Impact of TP53 Mutation on Survival Outcomes in Acute Lymphoblastic Leukemia at a Tertiary Center

Meera Patel, Ahmed N Mohamed, Hadil Zureigat, Emily C. Zabor, Daniel P. Nurse, Yohana B. Bedelu, Mark Jinan Chen, Joy Nakitandwe, Akriti G. Jain, John C. Molina, Sophia Balderman, Abhay Singh, Aaron T. Gerds, Sudipto Mukherjee, Hetty E. Carraway, Anjali S. Advani, Moaath K. Mustafa Ali

Blood (2024) 144 (Supplement 1): 4221.

https://doi.org/10.1182/blood-2024-199333

Published: 2024

Journal Articles

Decitabine Activity Against TP53 -Mutated Myeloid Neoplasms Is Enhanced By Combination with a Non-Cytotoxic p53/BAX-Independent Inhibitor of Pyrimidine Synthesis

Sudipta Biswas, Zeinab Albadry M. Zahran, Xiaorong Gu, Lisa Cardone, Akriti G. Jain, Kateryna Fedorov, Ben K. Tomlinson, Mendel Goldfinger, Amit Verma, Yogenthiran Saunthararajah

Blood (2024) 144 (Supplement 1): 1382.

https://doi.org/10.1182/blood-2024-210609

Published: 2024

Journal Articles

Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study

Blood (2024) 144 (Supplement 1): 1473.

https://doi.org/10.1182/blood-2024-205776

Published: 2024

Journal Articles

A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience

Blood (2024) 144 (Supplement 1): 1488.

https://doi.org/10.1182/blood-2024-206291

Published: 2024

Journal Articles

Epidemiological Trends in Incidence, Death and Associated Risk Factors of Leukemia 1990-2021 and Projection to 2040

Rupayan Kundu, Niladri Kal, Abhay Singh, Sudipto Mukherjee, Abhishek Maiti, Somedeb Ball, Akriti G. Jain

Blood (2024) 144 (Supplement 1): 1477.

https://doi.org/10.1182/blood-2024-211457

Published: 2024

Journal Articles

Survival Outcomes of Patients Diagnosed with Myeloid Sarcoma Versus Acute Myeloid Leukemia: A Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 4248.

https://doi.org/10.1182/blood-2024-205329

Published: 2024

NARROW

Evaluating Impact of Insertion Length on Clinical Outcomes in FLT3-ITD Mutated AML: A Single Center Retrospective Analysis

Impact of P190 and P210 BCR::ABL1 Chimeric Protein on Outcomes of Acute Lymphoblastic Leukemia at a Tertiary Center

Outcomes of Accelerated and Blast Phase Chronic Myeloid Leukemia at a Tertiary Center

Genetic Profiling and Survival Analysis of Patients with Acute Myeloid Leukemia and a History of Autoimmune Disease

A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes

Outcomes of Blast-Phase MPN and JAK2 , MPL , and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2 , MPL , and CALR Genes: A Propensity Score-Adjusted Cohort Study

Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia

Impact of Cytogenetic Response on Long-Term Survival in Acute Myeloid Leukemia: A Retrospective Cohort Study

Salvage Reinduction Chemotherapy Versus Alternative Regimens after Failed AML Intensive Induction Regimen, a Single Center Experience

Impact of Non- ABL1 Mutations on Outcomes in Patients with Chronic Myeloid Leukemia

Cardiovascular Profile of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia: A 16-Year Observational Study

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Outcomes of Second-Line Tyrosine Kinase Inhibitors after First-Line Imatinib in Chronic Myelogenous Leukemia: A Retrospective Cohort Study

Impact of TP53 Mutation on Survival Outcomes in Acute Lymphoblastic Leukemia at a Tertiary Center

Decitabine Activity Against TP53 -Mutated Myeloid Neoplasms Is Enhanced By Combination with a Non-Cytotoxic p53/BAX-Independent Inhibitor of Pyrimidine Synthesis

Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study

A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience

Epidemiological Trends in Incidence, Death and Associated Risk Factors of Leukemia 1990-2021 and Projection to 2040

Survival Outcomes of Patients Diagnosed with Myeloid Sarcoma Versus Acute Myeloid Leukemia: A Retrospective Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only